共 50 条
- [1] STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial (vol 374, pg 796, 2009)LANCET, 2009, 374 (9707): : 2054 - 2054Lennox, J. L.DeJesus, E.Lazzarin, A.
- [2] Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialLANCET, 2009, 374 (9692): : 796 - 806Lennox, Jeffrey L.Dejesus, EdwinLazzarin, AdrianoPollard, Richard B.Ramalho Madruga, Jose ValdezBerger, Daniel S.Zhao, JingXu, XioWilliams-Diaz, AngelaRodgers, Anthony J.Barnard, Richard J. O.Miller, Michael D.DiNubile, Mark J.Nguyen, Bach-YenLeavitt, RandiSklar, Peter
- [3] Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialLANCET, 2011, 378 (9787): : 238 - 246Molina, Jean-MichelCahn, PedroGrinsztejn, BeatrizLazzarin, AdrianoMills, AnthonySaag, MichaelSupparatpinyo, KhuanchaiWalmsley, SharonCrauwels, HertaRimsky, Laurence T.Vanveggel, SimonBoven, Katia
- [4] Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (06): : 884 - 891Andrade, AdrianaRosenkranz, Susan L.Cillo, Anthony R.Lu, DarleneDaar, Eric S.Jacobson, Jeffrey M.Lederman, MichaelAcosta, Edward P.Campbell, ThomasFeinberg, JudithFlexner, CharlesMellors, John W.Kuritzkes, Daniel R.
- [5] Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsLANCET, 2010, 375 (9712): : 396 - 407Eron, Joseph J.Young, BenjaminCooper, David A.Youle, MichaelDeJesus, EdwinAndrade-Villanueva, JaimeWorkman, CassyZajdenverg, RobertoFaetkenheuer, GerdBerger, Daniel S.Kumar, Princy N.Rodgers, Anthony J.Shaughnessy, Melissa A.Walker, Monica L.Barnard, Richard J. O.Miller, Michael D.DiNubile, Mark J.Nguyen, Bach-YenLeavitt, RandiXu, XiaSklar, Peter
- [6] Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trialLANCET, 2005, 366 (9500): : 1862 - 1867Bobat, RCoovadia, HStephen, CNaidoo, KLMcKerrow, NBlack, REMoss, W
- [8] Rapid and durable Antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection - Results of a 48-week controlled studyJAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (02) : 125 - 133Markowitz, MartinNguyen, Bach-YenGotuzzo, EduardoMendo, FernandoRatanasuwan, WinaiKovacs, ColinPrada, GuillermoMorales-Ramirez, Javier O.Crumpacker, Clyde S.Isaacs, Robin D.Gilde, Lucinda R.Wan, HongMiller, Michael D.Wenning, Larissa A.Teppler, Hedy
- [9] Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trialLANCET HIV, 2021, 8 (06): : E324 - E333Molina, Jean-MichelYazdanpanah, YazdanSaud, AlejandroBettacchi, ChristopherAnania, CarolinaDejesus, EdwinKlopfer, StephanieGrandhi, AnjanaEves, KarenRobertson, MichaelCorrell, ToddHwang, CareyHanna, GeorgeSklar, Peter
- [10] Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (vol 397, pg 2070, 2021)LANCET, 2021, 397 (10289): : 2048 - 2048Rovin, B. H.Teng, Y. K. O.Ginzler, E. M.